Financhill
Sell
49

LFST Quote, Financials, Valuation and Earnings

Last price:
$7.11
Seasonality move :
4.48%
Day range:
$7.13 - $7.27
52-week range:
$3.74 - $8.30
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
2.02x
P/B ratio:
1.86x
Volume:
884K
Avg. volume:
1.7M
1-year change:
-9.38%
Market cap:
$2.8B
Revenue:
$1.3B
EPS (TTM):
-$0.02

Analysts' Opinion

  • Consensus Rating
    Lifestance Health Group, Inc. has received a consensus rating of Buy. The company's average rating is a Buy based on 7 Buy ratings, 1 Hold rating, and 0 Sell ratings.
  • Price Target Upside
    According to analysts' consensus price target of $8.89, Lifestance Health Group, Inc. has an estimated upside of 24.32% from its current price of $7.15.
  • Price Target Downside
    According to analysts, the lowest downside price target is $8.00 representing 100% downside risk from its current price of $7.15.

Fair Value

  • According to the consensus of 8 analysts, Lifestance Health Group, Inc. has 24.32% upside to fair value with a price target of $8.89 per share.

LFST vs. S&P 500

  • Over the past 5 trading days, Lifestance Health Group, Inc. has overperformed the S&P 500 by 2.23% suggesting its relative strength compared to the major market average is strong at this time.

Share Buyback

  • Lifestance Health Group, Inc. does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.

Revenue Growth

  • Lifestance Health Group, Inc. has grown year-over-year revenues for 0 quarters straight. In the most recent quarter Lifestance Health Group, Inc. reported revenues of $363.8M.

Earnings Growth

  • Lifestance Health Group, Inc. has grown year-over-year earnings for 8 quarters straight. In the most recent quarter Lifestance Health Group, Inc. reported earnings per share of $0.00.
Enterprise value:
3.1B
EV / Invested capital:
--
Price / LTM sales:
2.02x
EV / EBIT:
361.03x
EV / Revenue:
2.23x
PEG ratio (5yr expected):
--
EV / Free cash flow:
25.56x
Price / Operating cash flow:
23.19x
Enterprise value / EBITDA:
47.35x
Gross Profit (TTM):
$388.3M
Return On Assets:
-0.43%
Net Income Margin (TTM):
-0.67%
Return On Equity:
-0.62%
Return On Invested Capital:
-0.47%
Operating Margin:
2.19%
Trailing 12 Months Fiscal Quarters
Period Ending 2023-09-30 2024-09-30 2025-09-30 2024-09-30 2025-09-30
Income Statement
Revenue $1B $1.2B $1.4B $312.7M $363.8M
Gross Profit $204.4M $297.8M $388.3M $85.3M $103M
Operating Income -$201.5M -$63.4M $8.5M $181K $8M
EBITDA -$124.4M $15.1M $64.4M $15.3M $21.5M
Diluted EPS -$0.51 -$0.25 -$0.02 -$0.02 $0.00
Period Ending 2021-09-30 2022-09-30 2023-09-30 2024-09-30 2025-09-30
Balance Sheet
Current Assets $328.3M $252.6M $264.3M $287M $360.4M
Total Assets $1.9B $2B $2.2B $2.1B $2.1B
Current Liabilities $105.2M $112.3M $240.9M $217.5M $228.6M
Total Liabilities $369.9M $448.2M $720M $670.8M $656.2M
Total Equity $1.5B $1.5B $1.5B $1.4B $1.5B
Total Debt $158.8M $214.2M $442.5M $440.7M $426.3M
Trailing 12 Months Fiscal Quarters
Period Ending 2023-09-30 2024-09-30 2025-09-30 2024-09-30 2025-09-30
Cash Flow Statement
Cash Flow Operations $2.2M $61.7M $150.9M $22.7M $27.3M
Cash From Investing -$79.2M -$26.7M -$31.5M -$5.1M -$10.3M
Cash From Financing $29.3M $25M -$18.1M -$2M -$2M
Free Cash Flow -$37.3M $35.1M $119.4M $17.7M $17M
LFST
Sector
Market Cap
$2.8B
$25.6M
Price % of 52-Week High
86.2%
49.47%
Dividend Yield
0%
0%
Shareholder Yield
0.22%
-1.77%
1-Year Price Total Return
-9.38%
-21.96%
Beta (5-Year)
--
0.499
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years

Technicals

8-day SMA
Buy
Level $7.04
200-day SMA
Buy
Level $5.78
Bollinger Bands (100)
Buy
Level 5.58 - 7.22
Chaikin Money Flow
Buy
Level 26.5M
20-day SMA
Buy
Level $7.04
Relative Strength Index (RSI14)
Buy
Level 54.71
ADX Line
Buy
Level 13.6
Williams %R
Neutral
Level -20.6659
50-day SMA
Buy
Level $7.07
MACD (12, 26)
Buy
Level 0.01
25-day Aroon Oscillator
Sell
Level -60
On Balance Volume
Neutral
Level 26.9M

Financial Scores

Hold
Altman Z-Score (Annual)
Level (2.215)
Buy
CA Score (Annual)
Level (0.3573)
Buy
Beneish M-Score (Annual)
Level (-2.8397)
Buy
Momentum Score
Level (3)
Sell
Ohlson Score
Level (0.6356)
Buy
Piotroski F Score (Annual)
Level (7)
Buy
Quality Ratio Score
Level (6)
Buy
Fundamental Score
Level (3)

Revenue Forecast

Earnings per Share Forecast

Company Profile

Lifestance Health Group, Inc. provides outpatient mental health services. It offers patients a suite of mental health services, including psychiatric evaluations and treatment, psychological, and neuropsychological testing, as well as individual, family, and group therapy. The firm operates outpatient mental health platform as well as offers patients care virtually through its online delivery platform or in-person at its centers in 32 states. The company was founded by Michael K. Lester, Gwen H. Booth and Danish J. Qureshi in 2017 and is headquartered in Scottsdale, AZ.

Stock Forecast FAQ

In the current month, LFST has received 7 Buy ratings 1 Hold ratings, and 0 Sell ratings. The LFST average analyst price target in the past 3 months is $8.89.

  • Where Will Lifestance Health Group, Inc. Stock Be In 1 Year?

    According to analysts, the consensus estimate is that Lifestance Health Group, Inc. share price will rise to $8.89 per share over the next 12 months.

  • What Do Analysts Say About Lifestance Health Group, Inc.?

    Analysts are divided on their view about Lifestance Health Group, Inc. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Lifestance Health Group, Inc. is a Sell and believe this share price will drop from its current level to $8.00.

  • What Is Lifestance Health Group, Inc.'s Price Target?

    The price target for Lifestance Health Group, Inc. over the next 1-year time period is forecast to be $8.89 according to 8 Wall Street analysts, 7 of them rate the stock a Buy, 0 rate the stock a Sell, and 1 analyst rates the stock a Hold.

  • Is LFST A Buy, Sell Or Hold?

    According to Wall Street analysts, the consensus rating for Lifestance Health Group, Inc. is a Buy. 7 of 8 analysts rate the stock a Buy at this time.

  • How Can I Buy Shares Of LFST?

    You can purchase shares of Lifestance Health Group, Inc. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Lifestance Health Group, Inc. shares.

  • What Is The Lifestance Health Group, Inc. Share Price Today?

    Lifestance Health Group, Inc. was last trading at $7.11 per share. This represents the most recent stock quote for Lifestance Health Group, Inc.. Yesterday, Lifestance Health Group, Inc. closed at $7.15 per share.

  • How To Buy Lifestance Health Group, Inc. Stock Online?

    In order to purchase Lifestance Health Group, Inc. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Popular

Is Celestica The Best AI Stock to Buy Now?
Is Celestica The Best AI Stock to Buy Now?

Technology and hardware business Celestica (NYSE:CLS) has seen massive upward…

Will AI Disrupt SaaS Software Stocks?
Will AI Disrupt SaaS Software Stocks?

Since January 28th, software stocks in the United States have…

Why Is Meta Stock Going Higher?
Why Is Meta Stock Going Higher?

Over the last five days, shares of Instagram and Facebook…

Stock Ideas

Buy
55
Is NVDA Stock a Buy?

Market Cap: $4.6T
P/E Ratio: 65x

Sell
50
Is AAPL Stock a Buy?

Market Cap: $3.9T
P/E Ratio: 35x

Sell
40
Is GOOGL Stock a Buy?

Market Cap: $3.8T
P/E Ratio: 29x

Alerts

Buy
77
RNG alert for Feb 23

RingCentral, Inc. [RNG] is down 12.48% over the past day.

Sell
9
FROG alert for Feb 23

JFrog Ltd. [FROG] is down 7.95% over the past day.

Buy
72
SNSE alert for Feb 23

Sensei Biotherapeutics, Inc. [SNSE] is down 2.63% over the past day.

THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS

Show me the best stock